Obstructive Sleep Apnea clinical trials

Explore recruiting obstructive sleep apnea clinical trials.

Recruiting obstructive sleep apnea studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Obstructive Sleep Apnea trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

TheRapeutic StrAtegies for Obstructive SleeP Apnea in Older Adults with OverweigHt or Obesity: A RandomizEd Clinical TriaL (RAPHAEL study)

Spain

Therapeutic use (Phase IV) EU CTIS Study details

A double blind, placebo controlled, parallel, study to evaluate the effects of NAL in Obstructive Sleep Apnea Patients.

France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

J5P-MC-GZRA: A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (ATTAIN-OSA); J5P-MC-GZ01: Participants with OSA unable or unwilling to use PAP therapy; J5P-MC-GZ02: Participants with OSA on PAP therapy

Czechia, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

PILOT STUDY OF THE EFFECT OF A SUBSTANCE P ANTAGONIST, APREPITANT, ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA AND ARTERIAL HYPERTENSION SYNDROME - (APHOS3)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

SYNERGY OSA - EFFICACY, SAFETY and TOLERABILITY OF COMBINED THERAPY WITH A SOMNOMED ORAL APPLIANCE AND THE CARBONIC ANHYDRASE INHIBITOR SULTHIAME IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA. A Randomized, Double-Blind, Placebo Controlled, Proof-of-Concept Trial

Denmark, Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

ObStructive Sleep Apnoea ManageMent in Older AdUlts with Overweight or ObEsity: A Randomized ClinicaL Trial (SAMUEL study)

Spain

Therapeutic use (Phase IV) EU CTIS Study details

Obstructive Sleep Apnea trials by city

Obstructive Sleep Apnea in Toronto Obstructive Sleep Apnea in Vancouver Obstructive Sleep Apnea in Montreal Obstructive Sleep Apnea in Calgary Obstructive Sleep Apnea in Edmonton Obstructive Sleep Apnea in Ottawa Obstructive Sleep Apnea in Winnipeg Obstructive Sleep Apnea in Quebec City Obstructive Sleep Apnea in Hamilton Obstructive Sleep Apnea in Kitchener Obstructive Sleep Apnea in London Obstructive Sleep Apnea in Halifax Obstructive Sleep Apnea in New York Obstructive Sleep Apnea in Los Angeles Obstructive Sleep Apnea in Chicago Obstructive Sleep Apnea in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease